Pressmeddelanden
Coegin Pharma provides NPP-4 development update - INCI registration filed and commercialization preparations on track.
Coegin Pharma AB ("Coegin" or the "Company") today provides an update on the development of NPP-4, the Company's next-generation cosmetic peptide innovation designed to enhance s...
REG
Communiqué from the Annual General Meeting of Coegin Pharma AB (publ)
Today, on May 21, 2026, the Annual General Meeting of Coegin Pharma AB (publ) ("Coegin Pharma" or the "Company") was held. A summary of the resolutions adopted follows below. All...
REG
Coegin Pharma AB publishes its interim report for the first quarter of 2026
Summary of interim reportThe first quarter of 2026 marked Coegin Pharma's transition from initial launch to commercial scale-up, with first commercial revenues from Follicopeptid...
Coegin Pharma's partner Mercapharm prepares major commercial launch of Follicopeptide® in Poland
Coegin Pharma AB ("Coegin" or the "Company") today announces that its Polish partner Mercapharm is preparing the commercial launch of Trichobalance, Mercapharm's new premium bran...
REG
Coegin Pharma AB publishes Annual Report for 2025
Coegin Pharma AB ("Coegin" or the "Company") today announces that the Annual Report for 2025 is available on the Company's website, www.coeginpharma.com, and is also attached to...
REG
Kallelse till årsstämma i Coegin Pharma AB (publ)
Aktieägarna i Coegin Pharma AB kallas härmed till årsstämma torsdagen den 21 maj 2026 kl. 10.00 på Medicon Village, Scheeletorget 1, i Lund.
Rätt att delta och anmälan Aktieägare...
Rapporter
Video
Finansiell kalender
Om Coegin Pharma
Coegin Pharma är ett svenskt innovationsbolag som utvecklar och kommersialiserar avancerade kosmetiska teknologier för hår och hud.
Webbplats
www.coeginpharma.com
Bransch
Bioteknik
Prenumerera
Få löpande information från Coegin Pharma via e-post.
Handelsinformation
Kurs 3,84 SEK (2026-06-05)
Förändring 7,26% (2025-06-05)